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Available online 14 December 2006Edited by Lukas HuberAbstract Danggui Buxue Tang (DBT), a Chinese herbal decoc-
tion used to treat ailments in women, contains Radix Astragali
(Huangqi; RA) and Radix Angelicae Sinensis (Danggui; RAS).
The weight ratio of RA to RAS used in DBT must be 5:1 as stip-
ulated as early as AD 1247; however, DBT’s mechanism of
action has never been described. Here, the estrogenic eﬀects of
DBT were investigated by determining the phosphorylations
of estrogen receptor a (ERa) and extracellular signal-regulated
kinase 1/2 (Erk1/2) in cultured MCF-7 cells. The application
of DBT triggered the phosphorylation of ERa and Erk1/2 in a
time-dependent manner. In contrast to the eﬀect of estrogen,
DBT triggered ERa phosphorylation at both S118 and S167.
This DBT-speciﬁc phosphorylation was not triggered by an ex-
tract of one of the individual herbs, or by mixing the extracts
of RA and RAS. DBT-induced downstream signals are described
here. These signals suggest the uniqueness of this Chinese herbal
decoction that requires a well-deﬁned formulation.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Women in menopause suﬀer from hot ﬂashes, sweating, anx-
iety, mood swings, as well as an increased risk for many health
problems, such as bone density reduction, cardiovascular dis-
ease and osteoporosis. These problems are largely due to the
deﬁciency of ovarian hormones, especially estrogen [1]. Hor-
mone replacement therapy (HRT) was introduced to allay
menopausal symptoms 20 years ago [2]. However, HRT re-
cently became a subject of debate because subject-based stud-
ies revealed an increased risk of breast cancer and coronaryAbbreviations:DBT, Danggui Buxue Tang; RA, Radix astragali; RAS,
Radix angelicae sinensis; ER, estrogen receptor; Erk, extracellular
signal-regulated kinase
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doi:10.1016/j.febslet.2006.12.018artery disease in women who use HRT [3,4]. In view of these
clinical risks, extensive eﬀorts have been devoted to developing
diﬀerent preparations that would yield the beneﬁts of hormone
therapy but with minimal inconvenience or risk [5]. Herbal
medicines are promising preparations and lead to fewer side
eﬀects [6]. Indeed, herbal products have become increasingly
popular in the last decade and are being used widely by women
in relieving their menopausal symptoms [7].
Among thousands of herbal formulae from traditional Chi-
nese medicine (TCM), Danggui Buxue Tang (DBT; a herbal
decoction) is a simple combination of two herbs. DBT was ﬁrst
described in Neiwaishang Bianhuo Lun by Li Dongyuan in
China in AD 1247. Li described the DBT formula that in-
cluded: 10 qian of Radix Astragali (RA), roots of Astragalus
membranaceus (Fisch.) Bunge or Astragalus membranaceus
(Fisch.) Bunge var.mongholicus (Bunge) P.K. Hsiao, and two
qian of Radix Angelicae Sinensis (RAS), roots of Angelica sin-
ensis (Oliv.) Diels. A Qian was the weight unit in ancient Chi-
na; one qian equals about 3 g. The mixed herbs were boiled in
two bowls of water over a moderate heat until the ﬁnal volume
was reduced by half. Traditionally, DBT has been prescribed
to women in China as a remedy for menopausal symptoms.
These women are directed to drink DBT daily to raise their
‘‘Qi’’ (their vital energy) and nourish their ‘‘Blood’’ (their body
circulation).
Pharmacological results indicated that DBT has the abilities
to promote hematopoietic functions, to stimulate cardiovascu-
lar circulation, to prevent osteoporosis, to increase anti-oxida-
tion activity and to stimulate the immune system [8,9]. By
determining the chemical and biological properties of DBT,
the optimized extraction conditions have been established
[8,10], which, interestingly, are in accord with the weight ratio
of 5:1 for RA to RAS in the ancient preparation.
The rationale for including diﬀerent herbs in Chinese herbal
decoctions has never been fully explained, which consequently
hinders the development of multi-herb decoctions as disease
and disorder remedies. In a pioneering eﬀort to reveal the
downstream signaling mechanisms of DBT, we employed
human breast cancer MCF-7 cell as a model system to deter-
mine the estrogenic activity of DBT via the activation of gene
transcription. Indeed, the estrogenic eﬀects are the primary
function of the DBT decoction. In addition, we revealed theblished by Elsevier B.V. All rights reserved.
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tions of estrogen receptor a (ERa) and extracellular signal-reg-
ulated kinase 1/2 (Erk1/2).2. Materials and methods
2.1. Plant materials and preparation of DBT
Fresh roots were obtained from China in September to October of
2002. We collected three-year-old A. membranaceus var. mongholicus
roots from Shanxi province and two-year-old A. sinensis roots from
Minxian in Gansu province. These areas had been demonstrated to
produce the best quality RA [11] and RAS [12], respectively. Prepara-
tion of the herb materials under optimized conditions was described
previously [10]. The corresponding vouchers as forms of whole plants,
voucher # 02-9-1 for A. membranaceus var.mongholicus and voucher #
02-10-4 for A. sinensis, were deposited in the Chinese medicinal plant
collection in the Department of Biology, The Hong Kong University
of Science and Technology, China. In preparing the DBT, exact
amounts of RAS and RA were weighed according to a ratio of 5:1
and then mixed well in a vortex. The mixture was boiled in 8 volumes
of water (v/w) for 2 h and extracted twice; this extraction followed the
ancient recipe that had been shown to have the best extracting condi-
tions [10]. Separate samples of RAS and RA were extracted by the
same method. The extracts were dried by lyophilization and stored
at 80 C.2.2. HPLC ﬁngerprinting of DBT
Ferulic acid was purchased from Sigma (St. Louis, MO), calycosin,
formononetin and ligustilide (z-isoform) were kindly provided by Prof.
Pengfei Tu, the Medical College of Peking University; their purities,
conﬁrmed by HPLC, were higher than 99.0%. AR- and HPLC-grade
reagents were from Merck (Darmstadt, Germany). A Waters (Milford,
MA) HPLC system consisting of a 600 pump, a 717 auto-sampler and
a UV/VIS Photodiode Array 2996 Detector was used for all analyses.
Chromatographic separations were carried out on a DELTA-PAK C18
column (particle size 4.6 lm, 3.9 mm · 150 mm) with acetonitrile (as
Solvent A) and: 0.01% phosphoric acid (as Solvent B) in the mobile
phase at a ﬂow rate of 1.0 ml/min at room temperature. A linear
gradient elution was applied from 15% to 65% of Solvent A starting
from 0 to 60 min. Samples were ﬁltered through a 0.45 lm Millipore
syringe ﬁlter unit. Twenty microliter samples were injected for HPLC
analysis.2.3. The MCF-7 cell culture
Human mammary epithelial carcinoma cell line MCF-7 was ob-
tained from American Type Culture Collection (ATCC) and was
grown in modiﬁed Eagle’s medium (MEM), supplemented with 10%
fetal bovine serum (FBS), 1 mM nonessential amino acids, 0.1 mM so-
dium pyruvate, 100 U/ml penicillin, and 100 lg/ml streptomycin in a
humidiﬁed CO2 (5%) incubator at 37 C. The culture reagents were
purchased from Invitrogen Technologies (Carlsbad, CA). Before plat-
ing, PBS was used to wash the cells, and the medium was changed to
MEM-a without phenol red containing 5% charcoal dextran-treated
FBS for 1 day. MCF-7 cells were seeded in a 24-well plate at 25000
cells/cm2. Three hours before the drug treatment, the medium was
changed to phenol-red free MEM-a. The cells were treated with
DBT and other samples for appropriate times at a ﬁnal concentration
of 1 mg/ml. In the blocking analyses, ER antagonist ICI 182780 (To-
cris, Ellisville, MO) at 0.1 lM and Erk1/2 inhibitors PD098059
(20 lM) and U0126 (10 lM; Sigma) were applied 3 h before the appli-
cation of other drugs. The positive control was 17b-estradiol (0.1 lM;
Sigma), dissolved in dimethyl sulfoxide (DMSO), or comparisons.
Phorbol 12-myristate 13-acetate (TPA; Sigma) at 0.1 lM was used as
the Erk1/2 activator.2.4. Estrogen promoter assay in the MCF-7 cells
Three repeats of estrogen responsive elements (ERE: 5 0-GGT CAC
AGT GAC C-3 0) were synthesized as described previously [13] and
then subcloned into a promoter-reporter vector called pTAL-Luc
(Clontech, Mountain View, CA) that has a downstream reporter of
the ﬁreﬂy luciferase gene; this DNA construct was named pERE-Luc. Cultured MCF-7 cells were transfected with pERE-Luc to gener-
ate stable cells according to a previous report [14]. To determine the
estrogenic properties, DBT or another extract was applied to the cul-
tures for 2 days. If necessary, the cultures were pretreated with ICI
182780, PD098059 and U0126 for 3 h before the drug application.
Afterward, the medium was aspirated, and MCF-7 cells were washed
by cold PBS. The cells were lysed with 100 ll/well of lysis buﬀer con-
taining 0.2% Triton X-100, 1 mM dithiothreitol and 100 mM potas-
sium phosphate buﬀer (pH 7.8) at 4 C. Following centrifugation at
14000 rpm and 4 C for 10 min, the supernatant was collected, and
50 ll of the supernatant was used to perform the luciferase assay (Tro-
pix Inc., Bedford, MA); the activity was normalized by equal amounts
of protein. The cell viability of the cultured MCF-7 cells was measured
by a 3-(4,5-dimethylthioazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Sigma) assay according to the manufacturer’s instructions by
measuring the absorbance at 570 nm.2.5. Determination of ERa and Erk 1/2 phosphorylation in MCF-7 cells
The phosphorylations of ERa at serine 118 (S118) and serine 167
(S167), and Erk1/2 were determined by western blot assays. Cultures
were serum starved for 3 h before the drug applications. After drug
treatments, including all the inhibitors or activators, the cultures were
collected immediately in lysis buﬀer (125 mM Tris–HCl, 2% SDS, 10%
glycerol, 200 mM 2-mercaptoethanol, pH 6.8) and the proteins were
subjected to SDS–PAGE analysis. After transferring the proteins to
membranes, the membranes were incubated with anti-phospho-ERa
S118 (Upstate, Lake Placid, NY) at 1:2000 dilution, anti-phospho-
ERa S167 at 1:1000 dilution (Upstate), or anti-phospho-Erk1/2 (Cell
Signaling, MA, USA) at 1:5000 dilution at 4 C for 12 h. Following
incubation in horseradish peroxidase (HRP)-conjugated anti-rabbit
secondary antibodies in 1:5000 dilutions for 1 h at room temperature,
the immuno-complexes were visualized by the enhanced chemilumines-
cence (ECL) method (Amersham Biosciences, Piscataway, NJ). The
band intensities in the control and agonist-stimulated samples, run
on the same gel and under strictly standardized ECL conditions, were
compared on an image analyzer, using in each case a calibration plot
constructed from a parallel gel with serial dilutions of one of the
samples.2.6. Other assays
The protein concentrations were measured routinely by Bradford’s
method with a kit from Bio-Rad Laboratories (Hercules, CA). Statis-
tical tests were run on the PRIMER program, version 1 (Primer of Bio-
statistics): diﬀerences from the basal or control values (as shown in the
ﬁgures) were classed as signiﬁcant [*] where P < 0.05, more signiﬁcant
[**] where P < 0.01 and highly signiﬁcant [***] where P < 0.001.3. Results
3.1. Standardization of DBT
DBT, composed of RA and RAS in a weight ratio of 5:1,
was prepared according to the optimized extraction conditions
as described previously [8,10]. In order to standardize the her-
bal extract chemically, we generated HPLC ﬁngerprints. Fig. 1
shows a typical HPLC ﬁngerprint of DBT at an absorbance of
254 nm. By discovering the amounts of two chemical markers
in RA (calycosin and formononetin) and two others in RAS
(ferulic acid and ligustilide), we were able to standardize the
weight ratio of 5:1 for optimal DBT. We found that standard-
ized DBT should contain 0.186 mg calycosin, 0.155 mg formo-
nonetin, 0.351 mg ferulic acid and 0.204 mg ligustilide per one
gram dried weight of DBT. From the extraction eﬃciency cal-
culations, we found that about 1.92 g of DBT was obtained
from 5 g RA mixed with 1 g RAS; the yield of DBT in this
weight ratio was 32 ± 3% (n = 5). These parameters established
the chemical standards and the optimal DBT mixture for the
remaining experiments.
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Fig. 1. Chemical standardization of DBT by HPLC ﬁngerprint analy-
sis. In the HPLC ﬁngerprint at an absorbance of 254 nm, the peaks
corresponding to ferulic acid (A), calycosin (B), formononetin (C) and
ligustilide (D) were identiﬁed. The details of the marker identiﬁcation
were described previously [11]. These chemical characterizations are
used to identify the standardized DBT for all the biochemical analyses.
A typical ﬁngerprint of DBT is shown, n = 5.
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A promoter-reporter construct (pERE-Luc; see Fig. 2b
upper panel) containing three repeats of estrogen-responsive
element was stably transfected into MCF-7 cells, and this sta-
ble cell line was used to determine the estrogenic eﬀect of DBT.
Diﬀerent amounts of DBT were applied to the cultures for 2
days. Two biological eﬀects were subsequently determined:
the cell viability and the promoter-driven luciferase activity.b
RA RAS
ß-Estradiol
DBT
RA + RAS
Estrogenic
activity
0
1
2
3
Lu
ci
fe
ra
se
ac
tiv
ity
 
( X
 B
as
al 
)
Ce
ll 
pr
ol
ife
ra
tio
n 
( X
 B
as
al 
)
a
0
1
2
Mitogenic
activity
Control
**
1 Day 2 Day
Fig. 2. DBT stimulates the transcriptional activity of the estrogen-responsive
estrogenic activities by DBT. pERE-Luc stably transfected MCF-7 cultures w
1 or 2 days and then were used to perform cell proliferation assays (MTT
(0.1 lM) was used as a positive control. Values of cell proliferation and prom
the basal reading where the control (without drug) equals to 1. **P < 0.01 as c
repeats of ERE in a luciferase promoter-reporter vector (upper panel). The
diﬀerent doses for 1 day (lower panel), and then the luciferase assay was pe
eﬀect of DBT. Data are expressed as means ± S.E.M., where n = 4, each witAs shown in Fig. 2a upper panel, RA, RAS and DBT were
not able to alter the mitogenic activity of MCF-7 cells in terms
of cell proliferation, even at high concentrations of DBT (data
not shown). In contrast, application of 17b-estradiol showed a
strong cell proliferation eﬀect on cultured MCF-7 cells, which
indicated a distinct cell proliferation eﬀect of DBT as com-
pared to estrogen. In the estrogen-regulated promoter activity
assay, diﬀerent herbal extracts were added to stably pERE-
Luc-transfected MCF-7 cells. As expected, 17b-estradiol at
0.1 lM, as a control, caused a 3-fold increase in the promoter
activity. The application of 1 mg/ml DBT led to activation of
the promoter, and the potency was the strongest among the
diﬀerent herbal extracts we tested (Fig. 2a lower panel). Appli-
cation of 1 mg/ml RA or 1 mg/ml RA + RAS (boiled sepa-
rately and then mixed together) also induced promoter
activity; however, the activity was lower when compared to
the activity of DBT (Fig. 2a lower panel). One milligram per
milliliter RAS did not have an activation eﬀect. The DBT-in-
duced pERE-Luc activity was similar after either 1 or 2 days
of treatment. In addition, the DBT treatment showed a dose-
dependent response in activating the pERE-driven luciferase
activity (Fig. 2b lower panel). The pretreatment of ICI
182780, an estrogen antagonist, fully blocked the response.
3.3. Phosphorylation of ERa by DBT
ERa belongs to a super family of ligand-activated transcrip-
tion factors, whose transcriptional activities are inﬂuenced by
various signaling messengers [15]. ERa can be phosphorylated
on multiple amino acid residues including S104, S106, S118,
S167, etc. Among all these possible phosphorylation sites,5’- GGTCACAGTGACC -3’
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Fig. 3. DBT induces the phosphorylation of ERa on S118. (a) MCF-7 cultures were serum starved for 3 h before the addition of DBT, RA, RAS and
RA + RAS extracts (1 mg/ml) for diﬀerent durations. b-Estradiol (0.1 lM) was used as a positive control. Total ERa and S118 phosphorylated ERa
(ERaS118-P), both at 66 kDa, were revealed by using speciﬁc antibodies. The lower panel shows the quantitation of phosphorylation from the blots
by calibrating the densitometer. (b) Cultures were pretreated with ICI 182780 at 0.1 lM for 3 h before the drug application. The inductive eﬀect of
DBT on ERa phosphorylation (S118) was blocked by ICI 182780. The lower panel shows the quantitation of phosphorylation from the blots at
60 min by calibrating the densitometer. Phosphorylation values are expressed as the ratio to the basal reading where time 0 (untreated as basal)
equals to 1, and in means ± S.E.M., where n = 4. ***P < 0.001 as compared to the control group.
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gen. Application of 17b-estradiol onto cultured MCF-7 cells
induced the phosphorylation of ERa at S118 (66 kDa); the
phosphorylation started 10 min after the drug application
and it lasted for at least 50 min (Fig. 3a). The phosphorylation
of S118 in ERa was also triggered by DBT, and this phosphor-
ylation lasted for at least 50 min (over ﬁvefold activation) after
the drug treatment (Fig. 3a). In contrast, extracts derived from
RA alone, RAS alone, or RA + RAS induced S118 phosphor-
ylation to a small extent with a 2-fold increase in the activity.
ICI 182780 belongs to a class of ‘pure’ anti-estrogen drugs
[16], which act as potent antagonists by inducing rapid recep-
tor turnover rates and blocking the agonistic activity both
in vivo and in vitro [17]. The pure antagonistic property of
ICI 182780 comes from its steroidal structure containing a
long bulky side chain that induces a distinct conformational
change in the ligand binding domain of ER [18]. Cultured
MCF-7 cells were pretreated with the antagonist (0.1 lM)
for 3 h before drug treatments. Results indicated that the
pretreatment of ICI 182780 completely blocked ERa phos-
phorylation at S118 that had been induced by DBT and 17b-
estradiol (Fig. 3b). The application of ICI 182780 induced
the basal S118 phosphorylation of ERa, and the application
was concomitant with down regulation of total ERa levels(Fig. 3b). These results agree with the results of a previous
report [19].
In addition to S118 phosphorylation, we also investigated
phosphorylation at S167 in ERa. Although the requirement
of S167 for estrogen activation remains controversial, the
phosphorylation of this serine residue provides evidence to
support the activation of ERa, as well as its function, in regu-
lating gene transcriptions [20]. In cultured MCF-7 cells, appli-
cation of 17b-estradiol or the extracts derived from RAS, RA,
RAS + RA did not induce ERa phosphorylation at S167. Sur-
prisingly, DBT induced a speciﬁc activation at S167; the acti-
vation increased by over 15-fold after the drug challenge
(Fig. 4a). The DBT-speciﬁc ERa phosphorylation of S167
was fully blocked through the pretreatment with ICI 182780
(Fig. 4b), suggesting a possible interaction of ERa with DBT.
3.4. Phosphorylation of Erk1/2 by DBT
Mitogen-activated protein kinases (MAPKs) are involved in
numerous cellular responses including cell growth and diﬀeren-
tiation, and they have been shown to participate in ERa phos-
phorylation. We chose to study the phosphorylation of Erk1/2,
an MAPK with a role in the classical Raf-MEK-Erk pathway.
Similar to our analysis of ERa phosphorylation, we treated
serum-starved MCF-7 cultures with diﬀerent drugs and col-
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Fig. 4. DBT induces the phosphorylation of ERa on S167. (a) MCF-7 cultures were serum starved for 3 h before the addition of DBT, RA, RAS and
RA + RAS extracts (1 mg/ml) for diﬀerent durations. Total ERa and S167 phosphorylated ERa (ERaS167-P) were revealed by using speciﬁc
antibodies. b-Estradiol (0.1 lM) was used as a positive control. The lower panel shows the quantitation of the phosphorylation from the blots by
calibrating the densitometer. (b) The inductive eﬀect of DBT on ERa phosphorylation (S167) was blocked by ICI 182780 (0.1 lM) pretreatment. The
lower panel shows the quantitation of phosphorylation from the blots at 60 min by calibrating the densitometer. Phosphorylation values are
expressed as the ratio to the basal reading where time 0 (untreated as basal) equals to 1, and in means ± S.E.M., where n = 4. ***P < 0.001 as
compared to the control group.
Q.T. Gao et al. / FEBS Letters 581 (2007) 233–240 237lected the cells at diﬀerent times. The phosphorylations of Erk1
(44 kDa) and Erk2 (42 kDa) were markedly increased with
addition of DBT with the maximal eﬀect of about 15-fold at
30 min after treatment. The activation was maintained longer
than 50 min after the start of the treatment (Fig. 5a). The
application of 17b-estradiol, which served as a control, in-
duced Erk1/2 phosphorylation at an extent similar to that of
DBT. In addition, the phosphorylation of Erk1/2 was insignif-
icant when MCF-7 cells were treated with RA, RAS, or the
mixture of RA + RAS (Fig. 5a).
We further conﬁrmed the role of Erk1/2 in activating ERa.
In cultured MCF-7 cells, the application of TPA (12-O-tetra-
decanoylphorbol 13-acetate), a known activator of Erk1/2, in-
duced the phosphorylation of Erk1/2 and ERa at both S118
and S167 residues (Fig. 5b). The time courses of these activa-
tions were very similar, i.e., the phosphorylations started after
15 min of TPA treatment and reached a maximum at about
30 min (Fig. 5b). These results showed that Erk1/2 could serve
as an upstream activator of ERa.
Two speciﬁc MAPK inhibitors, PD098059 and U0126, were
used to test the speciﬁcity of the DBT eﬀects. In the cultured
cells, both of the inhibitors fully blocked the DBT-induced
Erk1/2 phosphorylation (Fig. 6a and b). However, the inhibi-
tors only partially blocked the DBT-induced ERa phosphory-
lation at the S118 and S167 residues (Fig. 6a and b). The eﬀectsof PD098059 and U0126 in blocking the DBT-induced ERa
phosphorylation did not change even when the amount of
the inhibitors was increased (data not shown), which suggested
that the eﬀect of DBT in phosphorylating ERa was not fully
explained by Erk1/2 only. The amounts of total Erk and
ERa did not change. We suggest two possible pathways to ac-
count for the DBT-induced ERa phosphorylation: (1) Erk-
dependent and (2) Erk-independent signaling pathways. In line
with this suggestion, we observed that the MAPK inhibitors
only partially blocked the DBT-induced estrogenic activity in
pERE-Luc- transfected MCF-7 cells (Fig. 6c).4. Discussion
By analyzing the downstream signaling pathway(s) of DBT-
induced estrogenic eﬀects, we are able to provide evidence of
the uniqueness of a speciﬁc combination of RA and RAS in
creating the Chinese medicinal DBT. In addition, the estro-
genic activation of DBT is very distinct from that of estrogen
as shown in the speciﬁc phosphorylation of ERa at S167 in
DBT-treated breast cancer cells. Although the activity of the
estrogen-responsive element in pERE-Luc stably expressing
MCF-7 cells could be activated by extracts of individual herbs,
or by a mixture of RA and RAS, the phosphorylations of ERa
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Fig. 5. DBT and TPA induce Erk1/2 and ERa phosphorylation. (a) MCF-7 cultures were serum starved for 3 h before the addition of DBT, RA,
RAS and RA + RAS extracts (1 mg/ml) for diﬀerent times. Total and phosphorylated Erk1/2 were revealed by using speciﬁc antibodies. b-Estradiol
(0.1 lM) was used as a positive control. The lower panel shows the quantitation of phosphorylation from the blots by calibrating the densitometer.
(b) Cultured MCF-7 cells were treated with 0.1 lM TPA for 45 min and then collected to determine the protein phosphorylation with antibodies
against S118 and S167 phosphorylated ERa and phosphorylated Erk1/2. Total proteins were served as the loading control in all cases. The lower
panel shows the quantitation of phosphorylation from the blots by calibrating the densitometer. Phosphorylation values are expressed as the ratio to
the basal reading where time 0 (untreated as basal) equals to 1, and in means ± S.E.M., where n = 4.
238 Q.T. Gao et al. / FEBS Letters 581 (2007) 233–240at S167 and of Erk1/2 were found only in DBT-treated cul-
tures. The speciﬁc DBT-induced phosphorylations, therefore,
suggested that boiling the two herbs together is essential; this
method of preparation of DBT, indeed, has long been recom-
mended by TCM practitioners in China. In addition to the
study with MCF-7 cells, the role of the correct weight ratio
of RA to RAS has also been demonstrated in cultured osteo-
blasts [8] and T-lymphocytes [9]. Interestingly, the biological
properties of DBT as demonstrated here are in agreement with
the preparation and usage of DBT as ﬁrst described about 800
years ago.
Besides S167 phosphorylation, DBT also had distinct eﬀects
on S118 phosphorylation of ERa. Although both DBT and
estrogen could phosphorylate ERa on S118, the phosphoryla-
tion proﬁles were diﬀerent in time and magnitude. For in-
stance, the phosphorylation induced by DBT started at
40 min after treatment with 5-fold greater activation, which
was much slower and less intense than treatment with 17b-
estradiol. The distinctive eﬀects of DBT on S118 and S167
phosphorylations might correlate with the inability of DBT
to stimulate the proliferation of cultured MCF-7 cells. ERa
could be phosphorylated by direct binding with estrogen,
and/or the phosphorylation could be mediated by other signal-
ing molecules. For instance, the phosphorylation of ERa S118could be mediated by CDK7 in responding to 17b-estradiol,
which was also phosphorylated by Erk1/2 [21,22]. S167 of
ERa is a target site for protein kinase B (Akt) and ribosomal
S6 kinase (p90RSK) [23,24]. Additionally, both of the two ki-
nases could be activated by Erk1/2 [24,25]. Therefore, the spe-
ciﬁc eﬀect of DBT on Erk1/2 phosphorylation could possibly
account for the ERa phosphorylations on S118 and S167,
which subsequently stimulate the transcription of the estro-
gen-responsive genes. Thus, we suggest that the activation of
ERa by DBT is diﬀerent from a classical activation pathway
mediated by estrogen, which requires further elucidation.
In agreement with the ancient formulation, the 800-year-old
decoction described here with RA and RAS in a 5:1 ratio pos-
sesses the best biological activities in stimulating estrogenic re-
sponses [8] as well as immunological responses [9]. In
agreement with our previous results, we have demonstrated
the speciﬁc requirement of boiling the two herbs together dur-
ing DBT preparation to achieve full biological activity. Why
boiling the two herbs together leads to better outcomes re-
mains an unanswered question. We oﬀer two hypotheses to ex-
plain the unique biological functions of DBT. First, DBT
might contain additional chemicals than those in the extracts
of RA or RAS. Very likely, these additional chemicals are only
soluble in DBT, i.e., the boiling of RA and RAS together en-
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Fig. 6. The DBT-induced estrogenic eﬀects are partially blocked by
Erk1/2 inhibitors. (a) MCF-7 cultures were pretreated with buﬀer
(0.1% DMSO), 20 lM PD098059 and 10 lM U0126 for 3 h before the
addition of DBT (1 mg/ml) for 30 min. Cultures were collected to
determine the ERa and Erk1/2 phosphorylations. Total proteins were
served as the loading control in all cases. (b) The quantitation of
phosphorylations from the blots in (a) was done by calibrating the
densitometer. (c) The pERE-Luc transfected MCF-7 cultures were
pretreated with inhibitors as in (a) before the addition of DBT for 2
days. Cultures were then collected to determine the luciferase activity.
Phosphorylation values or the promoter-driven luciferase activities are
expressed as the ratio to the basal or control reading where time 0 or
untreated culture equals to 1, and in means ± S.E.M., where n = 4.
**P < 0.01 as compared to the buﬀer control.
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cals could be responsible for the distinct DBT-speciﬁc eﬀects.
The optimized ratio of the two herbs in yielding more active
ingredients can be a good explanation for the DBT-speciﬁceﬀects. Our chemical analyses showed that higher amounts
of RA-derived astragaloside IV, calycosin, formononetin,
and RAS-derived ferulic acid were found in the DBT decoc-
tion; there was as much as double the amount of these chem-
icals in the 5:1 ratio than in other ratios of RA to RAS [8].
Second, there could be a synergistic eﬀect of diﬀerent compo-
nents in DBT; this synergistic eﬀect is not present in the ex-
tracts of the single herbs. Unfortunately, we do not have
direct evidence to test these hypotheses from our DBT experi-
ments. However, because of the failure of the RA + RAS mix-
ture to perform the same functions as DBT, we believe that the
second hypothesis is less likely.
It is well known that steroid hormones, especially estrogen,
can induce cell proliferation, which subsequently may lead to
an increase risk of developing breast cancer. Indeed, this issue
is a major concern in the use of estrogen replacement therapy.
In contrast, DBT did not alter the proliferation of MCF-7
cells, even at high concentrations. In accordance with this
observation, patients with breast tumors with high phosphor-
ylation on ERa S167 responded positively to endocrine ther-
apy, and these patients had a better survival rate [26]. In
view of the aforementioned characteristics, DBT could serve
as a novel therapeutic treatment to replace estrogen to relieve
menopausal symptoms.
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